Vernalis plc (LON:VER) insider David Mackney sold 27,233 shares of the business’s stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($13,144.64).

Vernalis plc (LON:VER) opened at 40.00 on Friday. The firm’s market capitalization is GBX 210.48 million. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 75.00. The firm’s 50-day moving average is GBX 42.41 and its 200 day moving average is GBX 44.80.

Several analysts have issued reports on the stock. Canaccord Genuity reissued a “buy” rating and set a GBX 84 ($1.04) target price on shares of Vernalis plc in a research note on Tuesday, September 6th. Shore Capital reaffirmed a “house stock” rating on shares of Vernalis plc in a research note on Tuesday, July 19th. Stifel Nicolaus upped their price target on shares of Vernalis plc from GBX 94 ($1.16) to GBX 99 ($1.23) and gave the stock a “buy” rating in a research note on Tuesday, September 6th. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 76 ($0.94) price target on shares of Vernalis plc in a research note on Friday, July 8th. Finally, N+1 Singer reaffirmed a “hold” rating and issued a GBX 46 ($0.57) price target on shares of Vernalis plc in a research note on Thursday, September 29th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of GBX 73 ($0.90).

About Vernalis plc

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.

Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.